• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Alefacept response lingers in psoriatic patients

New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.

Related Videos
Related Content
Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD
March 12th 2025

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Understanding and Treating Pediatric AD Inside and Out
March 4th 2025

Understanding and Treating Pediatric AD Inside and Out

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Reviewing Complex Cases: Topicals for Pediatric AD
February 25th 2025

Reviewing Complex Cases: Topicals for Pediatric AD

Study Finds Propranolol Initiation for Infantile Hemangiomas Safe with Less Monitoring
February 25th 2025

Study Finds Propranolol Initiation for Infantile Hemangiomas Safe with Less Monitoring

© 2025 MJH Life Sciences

All rights reserved.